Literature DB >> 21160853

Impact of metastatic lymph node ratio in node-positive colorectal cancer.

Shingo Noura1, Masayuki Ohue, Shingo Kano, Tatsushi Shingai, Terumasa Yamada, Isao Miyashiro, Hiroaki Ohigashi, Masahiko Yano, Osamu Ishikawa.   

Abstract

Colorectal cancer (CRC) is one of the most common malignant diseases in the world. Presently, the most widely used staging system for CRC is the tumor nodes metastasis classification system, which classifies patients into prognostic groups according to the depth of the primary tumor, presence of regional lymph node (LN) metastases, and evidence of distant metastatic spread. The number of LNs with confirmed metastasis is related to the severity of the disease, but this number depends on the number of LNs retrieved, which varies depending on patient age, tumor grade, surgical extent, and tumor site. Numerous studies and a recent structured review have demonstrated associated improvements in the survival of CRC patients with increasing numbers of LNs retrieved for examination. Hence, the impact of lymph node ratio (LNR), defined as the number of metastatic LNs divided by the number of LNs retrieved, has been investigated in various malignancies, including CRC. In this editorial, we review the literature demonstrating the clinicopathological significance of LNR in CRC patients. Some reports have indicated the advantage of considering the LNR compared to the number of LNs retrieved and/or LN status. When the LNR is taken into consideration for survival analysis, the number of LNs retrieved and/or the LN status is not always found to be a prognostic factor. The cut-off points for LNRs were proposed in numerous studies. However, optimal thresholds for LNRs have not yet received consensus. It is still unclear whether the LNR has more prognostic validity than N stage. For all these reasons, the potential advantages of LNRs in the staging system should be investigated in large prospective data sets.

Entities:  

Keywords:  Colorectal cancer; Lymph node; Lymph node ratio; Prognostic factor; Tumor nodes metastasis stage

Year:  2010        PMID: 21160853      PMCID: PMC2999220          DOI: 10.4240/wjgs.v2.i3.70

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  58 in total

1.  Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT).

Authors:  L P Fielding; P A Arsenault; P H Chapuis; O Dent; B Gathright; J D Hardcastle; P Hermanek; J R Jass; R C Newland
Journal:  J Gastroenterol Hepatol       Date:  1991 Jul-Aug       Impact factor: 4.029

2.  Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.

Authors:  Carlos A Vaccaro; Victor Im; Gustavo L Rossi; Guillermo Ojea Quintana; Mario L Benati; Diego Perez de Arenaza; Fernando A Bonadeo
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

3.  Lymph node evaluation as a colon cancer quality measure: a national hospital report card.

Authors:  Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; Mark S Talamonti; David P Winchester; Thomas R Russell; Clifford Y Ko
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

4.  For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.

Authors:  S Caplin; J P Cerottini; F T Bosman; M T Constanda; J C Givel
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860

5.  Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.

Authors:  Robert Rosenberg; Jan Friederichs; Tibor Schuster; Ralf Gertler; Matthias Maak; Karen Becker; Anne Grebner; Kurt Ulm; Heinz Höfler; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

6.  The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.

Authors:  Frédérique Peschaud; Peschaud Frédérique; Stéphane Benoist; Benoist Stéphane; Catherine Julié; Julié Catherine; Alain Beauchet; Beauchet Alain; Christophe Penna; Penna Christophe; Philippe Rougier; Rougier Philippe; Bernard Nordlinger
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.

Authors:  Chih-Chien Chin; Jeng-Yi Wang; Chien-Yuh Yeh; Yi-Hung Kuo; Wen-Shih Huang; Chung-Hung Yeh
Journal:  Int J Colorectal Dis       Date:  2009-05-29       Impact factor: 2.571

8.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

9.  The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer.

Authors:  Wen-Hu Hsu; Po-Kuei Hsu; Chih-Cheng Hsieh; Chien-Sheng Huang; Yu-Chung Wu
Journal:  J Gastrointest Surg       Date:  2009-08-12       Impact factor: 3.452

10.  Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?

Authors:  Jiping Wang; Mahmoud Kulaylat; Howard Rockette; James Hassett; Ashwani Rajput; Kelli Bullard Dunn; Merril Dayton
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

View more
  16 in total

1.  The prognostic value of lymph node ratio and updated TNM classification in rectal cancer patients with adequate versus inadequate lymph node dissection.

Authors:  T Junginger; U Goenner; A Lollert; D Hollemann; M Berres; M Blettner
Journal:  Tech Coloproctol       Date:  2014-03-19       Impact factor: 3.781

2.  Neurokinin-2 receptor polymorphism predicts lymph node metastasis in colorectal cancer patients.

Authors:  Weijia Fang; Caiyun Fu; Xiaogang Chen; Xiaozhou Mou; Fanlong Liu; Jiong Qian; Peng Zhao; Yulong Zheng; Y I Zheng; Jing Deng; Pingjiang Ye; Yifei Wang; Shusen Zheng
Journal:  Oncol Lett       Date:  2015-03-06       Impact factor: 2.967

Review 3.  Colorectal cancer and lymph nodes: the obsession with the number 12.

Authors:  Giovanni Li Destri; Isidoro Di Carlo; Roberto Scilletta; Beniamino Scilletta; Stefano Puleo
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

4.  Adequate lymph node recovery improves survival in colorectal cancer patients.

Authors:  Adedayo A Onitilo; Rachel V Stankowski; Jessica M Engel; Suhail A R Doi
Journal:  J Surg Oncol       Date:  2013-04-16       Impact factor: 3.454

5.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

6.  The value of lymph node ratio in the prediction of rectal cancer patient survival after preoperative chemoradiotherapy.

Authors:  Li Chen; Xuefeng Huang; Zhangfa Song
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

7.  Impact on Prognosis of Lymph Node Micrometastasis and Isolated Tumor Cells in Stage II Colorectal Cancer.

Authors:  Tai Young Oh; Sun Mi Moon; Ui Sup Shin; Hyang Ran Lee; Sun Hoo Park
Journal:  J Korean Soc Coloproctol       Date:  2011-04-30

8.  Integrated ratio of metastatic to examined lymph nodes and number of metastatic lymph nodes into the AJCC staging system for colon cancer.

Authors:  Peng Gao; Yong-xi Song; Zhen-ning Wang; Ying-ying Xu; Lin-lin Tong; Jin-liang Zhu; Qing-chao Tang; Hui-mian Xu
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study.

Authors:  Norbert Marschner; Dirk Arnold; Erik Engel; Ulrich Hutzschenreuter; Jacqueline Rauh; Werner Freier; Holger Hartmann; Melanie Frank; Martina Jänicke
Journal:  Clin Epidemiol       Date:  2015-04-20       Impact factor: 4.790

10.  Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment.

Authors:  Yuji Toiyama; Hiroyuki Fujikawa; Yuki Koike; Susumu Saigusa; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Chikao Miki; Masato Kusunoki
Journal:  Oncol Lett       Date:  2013-04-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.